Fig. 1: Treatment history and evolution of tumor burden on lorlatinib and capmatinib. | npj Precision Oncology

Fig. 1: Treatment history and evolution of tumor burden on lorlatinib and capmatinib.

From: Lorlatinib and capmatinib in a ROS1-rearranged NSCLC with MET-driven resistance: tumor response and evolution

Fig. 1

A Timeline summarizing the treatment course and tumor and plasma sampling. Chemo: chemotherapy. B Representative computed tomography (CT) and brain magnetic resonance imaging (MRI) images demonstrating response to, and progression on, lorlatinib plus capmatinib therapy at the indicated time points, including the response of left axillary lymph node (yellow arrow), chest wall disease (yellow arrow), pleural thickening (yellow arrowhead), and liver metastasis (yellow arrow) to lorlatinib plus capmatinib dual therapy at 10 weeks; increasing liver metastasis (red arrow), new abdominal lymphadenopathy (red arrowhead), and new left temporal brain metastasis (red arrowhead). C Measurements on indicated metastatic lesions over the treatment course. Time 0 = baseline scan prior to initiation of lorlatinib plus capmatinib.

Back to article page